Clinical trial

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

NCT07794670

Study summary

ClinicalTrials.gov

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Obicetrapib 10 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Matching placebo tablets Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-09-01

PhasePHASE2

Conditions

Preclinical Alzheimer's Diseaseunresolved

Interventions

Obicetrapib 10 mgDRUG

Matching placebo tabletsDRUG

Sponsors & collaborators

NewAmsterdam Pharmalead sponsor

Mapped research locations

NashvilleTennessee, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07794670 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.